Literature DB >> 2553190

Inotropic response to DPI 201-106 in the failing human heart.

M Böhm1, F Diet, B Kemkes, M Wankerl, E Erdmann.   

Abstract

1. The present study was designed to characterize the positive inotropic response to DPI 201-106 in isolated papillary muscle strips obtained from heart failure patients undergoing surgery. 2. The positive inotropic responses to isoprenaline and milrinone and cardiac beta-adrenoceptor density were also determined. 3. DPI 201-106 increased the force of contraction in papillary muscle strips from patients with moderate (NYHA II-III) and severe (NYHA IV) heart failure, in a concentration-dependent manner. This positive inotropic effect was more pronounced in tissues from NYHA IV patients. Furthermore, these responses were greater than those produced by milrinone or isoprenaline. The positive inotropic effects of isoprenaline and milrinone were reduced in NYHA IV compared to NYHA II-III. Consistently, there was also a smaller density of beta-adrenoceptors in myocardium from NYHA IV than in NYHA II-III. The positive inotropic effect of Ca2+ was similar in tissues from both groups of patients. 4. The positive inotropic effect of DPI 201-106 was not antagonized by adenosine or carbachol, whereas both compounds reduced the positive inotropic effect of isoprenaline. 5. DPI 201-106 did not increase the Ca2+ -sensitivity of chemically skinned ventricular fibres, whereas a significant increase of the Ca2+ -sensitivity was obtained with trifluoperazine. 6. It is concluded that DPI 201-106 produces significant positive inotropic effects in tissue excised from the failing human heart. The lack of inhibition by adenosine and carbachol might contribute to its greater effectiveness in NYHA IV than NYHA II-III and indicates that its mechanism of action is cyclic AMP-independent. A sensitization of the contractile proteins to Ca2+ does not appear to be important for the positive inotropic action of DPI 201-106 in the failing human heart.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2553190      PMCID: PMC1854676          DOI: 10.1111/j.1476-5381.1989.tb16892.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  20 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  Adenosine as inhibitor of myocardial effects of catecholamines.

Authors:  J Schrader; G Baumann; E Gerlach
Journal:  Pflugers Arch       Date:  1977-11-25       Impact factor: 3.657

3.  Functional evidence for the existence of adenosine receptors in the human heart.

Authors:  M Böhm; W Meyer; A Mügge; W Schmitz; H Scholz
Journal:  Eur J Pharmacol       Date:  1985-10-22       Impact factor: 4.432

4.  Calculator programs for computing the composition of the solutions containing multiple metals and ligands used for experiments in skinned muscle cells.

Authors:  A Fabiato; F Fabiato
Journal:  J Physiol (Paris)       Date:  1979

5.  Increased adenosine formation by rat myocardium with acute aortic constriction.

Authors:  D H Foley; J T Herlihy; C I Thompson; R Rubio; R M Berne
Journal:  J Mol Cell Cardiol       Date:  1978-03       Impact factor: 5.000

6.  Release of adenosine from human hearts during angina induced by rapid atrial pacing.

Authors:  A C Fox; G E Reed; E Glassman; A J Kaltman; B B Silk
Journal:  J Clin Invest       Date:  1974-05       Impact factor: 14.808

7.  The role of sodium channels in the effects of the cardiotonic compound DPI 201-106 on contractility and membrane potentials in isolated mammalian heart preparations.

Authors:  D Buggisch; G Isenberg; U Ravens; G Scholtysik
Journal:  Eur J Pharmacol       Date:  1985-12-03       Impact factor: 4.432

8.  Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts.

Authors:  M R Bristow; R Ginsburg; W Minobe; R S Cubicciotti; W S Sageman; K Lurie; M E Billingham; D C Harrison; E B Stinson
Journal:  N Engl J Med       Date:  1982-07-22       Impact factor: 91.245

9.  Increased myocardial adenosine release in heart failure.

Authors:  W H Newman; S J Grossman; M B Frankis; J G Webb
Journal:  J Mol Cell Cardiol       Date:  1984-06       Impact factor: 5.000

10.  DPI 201-106, a novel cardioactive agent. Combination of cAMP-independent positive inotropic, negative chronotropic, action potential prolonging and coronary dilatory properties.

Authors:  G Scholtysik; R Salzmann; R Berthold; J W Herzig; U Quast; R Markstein
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-05       Impact factor: 3.000

View more
  5 in total

1.  Mg-ATPase and Ca+ activated myosin AtPase activity in ventricular myofibrils from non-failing and diseased human hearts--effects of calcium sensitizing agents MCI-154, DPI 201-106, and caffeine.

Authors:  Chukwuka Okafor; Ronglih Liao; Cynthia Perreault-Micale; Xiaoping Li; Toshiro Ito; Anna Stepanek; Angelia Doye; Pieter de Tombe; Judith K Gwathmey
Journal:  Mol Cell Biochem       Date:  2003-03       Impact factor: 3.396

2.  Myofilament calcium regulation in human myocardium.

Authors:  R J Hajjar; R H Schwinger; U Schmidt; C S Kim; D Lebeche; A A Doye; J K Gwathmey
Journal:  Circulation       Date:  2000-04-11       Impact factor: 29.690

3.  The inotropic agents DPI 201-106 and BDF 9148 differentially affect potassium currents of guinea-pig ventricular myocytes.

Authors:  G J Amos; U Ravens
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-10       Impact factor: 3.000

Review 4.  [Alterations of the cAMP-adenylate cyclase system in the failing human heart. Consequences for the therapy with inotropic drugs].

Authors:  M Böhm; R H Schwinger; E Erdmann
Journal:  Klin Wochenschr       Date:  1990-09-14

Review 5.  [Ca2+]i in human heart failure: a review and discussion of current areas of controversy.

Authors:  R Liao; P A Helm; R J Hajjar; C Saha; J K Gwathmey
Journal:  Yale J Biol Med       Date:  1994 Sep-Dec
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.